Clinical Trials Logo
  1. Home
  2. GVHD
  3. NCT03605927

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD Clinical Trial

Official title:
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.

Clinical Trial Description

The approach builds upon extensive evidence supporting the benefit of CD40L blockade in disrupting key signaling events associated with immune activation. The trial addresses a pressing clinical need, namely prevention of Graft-Versus-Host Disease (GVHD) after hematopoietic cell transplantation (HCT) and promotion of donor-recipient immune tolerance. The safety profile of this anti-CD40L antibody overcomes major prior limitations, and the planned biologic studies will provide significant mechanistic insight. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03605927
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Completed
Phase Phase 1
Start date February 15, 2019
Completion date September 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Terminated NCT01940796 - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) Phase 1
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Not yet recruiting NCT06075225 - MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Phase 2
Not yet recruiting NCT06000982 - Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis Phase 3
Active, not recruiting NCT03680092 - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06083129 - Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Phase 3
Not yet recruiting NCT05094765 - Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD Early Phase 1
Active, not recruiting NCT05415410 - Proof-of-concept Trial of Apraglutide in GVHD Phase 2
Completed NCT02441075 - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 N/A
Completed NCT02588339 - Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Phase 2
Not yet recruiting NCT06334367 - Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT Phase 2
Completed NCT03846479 - Itacitinib for Low Risk GVHD Phase 2
Completed NCT02891603 - A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Phase 1/Phase 2
Completed NCT02712762 - Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
Completed NCT03945591 - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Not yet recruiting NCT06411184 - Safety and Efficacy of Treg Cell in the Treatment of GVHD Phase 1/Phase 2
Terminated NCT02338232 - Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation N/A